SMITHKLINE'S FAILURE TO FORWARD SELACRYN REPORTS TO FDA FROM FRENCH DRUG DEVELOPER ANPHAR IS BASIS OF JUSTICE DEPT.'s 34 CHARGES AGAINST THE FIRM